Sanofi's prostate cancer drug Jevtana is not worth using on Britain's state health service, given its limited ability to extend life, its side effects and its cost, the healthcare watchdog NICE said on Friday. The draft guidance from the National Institute for Health and Clinical Excellence (NICE) is now open for consultation before further decisions on the medicine are made. Jevtana has been licensed for use in both Europe and the United States after clinical trials showed it helped men with advanced prostate cancer when given alongside the anti-inflammatory drug prednisone.